{
    "id": "342983dc-ded9-2234-e063-6294a90ac97f",
    "indications": {
        "text": "repaglinide tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus . limitation : repaglinide tablets used patients type 1 diabetes mellitus treatment diabetic ketoacidosis .",
        "doid_entities": [
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes mellitus (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "type 1 diabetes mellitus (DOID:9744)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9744"
            },
            {
                "text": "diabetic ketoacidosis (DOID:1837)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1837"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting dose 0.5 mg orally meal hba1c less 8 % ; 1 2 mg orally meal hba1c 8 % greater . ( 2.1 ) recommended dose range 0.5 mg 4 mg meals , maximum daily dose 16 mg. ( 2.1 ) patient \u2019 dose doubled 4 mg meal satisfactory glycemic control achieved . least one week elapse assess response dose adjustment . ( 2.1 ) instruct patients skip dose repaglinide tablets meal skipped . patients experience hypoglycemia , dose repaglinide tablets reduced . ( 2.1 ; 5.1 ) instruct patients take repaglinide tablets within 30 minutes meals . ( 2.1 ) patients severe renal impairment ( crcl = 20 \u2013 40 ml/min ) , recommended starting dose 0.5 mg orally meal . ( 2.2 ) dose modifications required used concominantly medications . ( 2.3 , 7 )",
        "doid_entities": [
            {
                "text": "hypoglycemia (DOID:9993)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9993"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "repaglinide tablets , usp available follows : 0.5 mg , white off-white colored , round tablet debossed \u2018 ce \u2019 one side \u2018 251 \u2019 side . ndc 62135-946-90 , bottle 90 tablets 1 mg , yellow pale yellow , slightly mottled , round tablet debossed \u2018 ce \u2019 one side \u2018 252 \u2019 side . ndc 62135-947-90 , bottle 90 tablets 2 mg , yellow pale yellow , slightly mottled , capsule shaped tablet debossed \u2018 ce \u2019 one side \u2018 253 \u2019 side . ndc 62135-948-90 , bottle 90 tablets store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) [ usp controlled room temperature ] . protect moisture . keep bottles tightly closed . dispense tight containers safety closures .",
    "adverseReactions": "repaglinide tablets contraindicated patients : concomitant gemfibrozil [ ( 7.1 ) ] . known hypersensitivity repaglinide inactive ingredients .",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MEGLUMINE",
            "code": "6HG8UB2MUY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09415"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "POLACRILIN POTASSIUM",
            "code": "0BZ5A00FQU"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "REPAGLINIDE",
            "code": "668Z8C33LU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8805"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Chartwell RX, LLC",
    "name": "Repaglinide",
    "effectiveTime": "20250502",
    "indications_original": "Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.\n                  \n                     Limitation of Use:\n                  \n                  Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.",
    "contraindications_original": "The recommended starting dose is 0.5 mg orally before each meal if HbA1c is less than 8%; and 1 or 2 mg orally before each meal if HbA1c is 8% or greater. ( 2.1 ) The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. ( 2.1 ) The patient\u2019s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment. ( 2.1 ) Instruct patients to skip the dose of repaglinide tablets if a meal is skipped. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced. ( 2.1 ; 5.1 ) Instruct patients to take repaglinide tablets within 30 minutes before meals. ( 2.1 ) In patients with severe renal impairment (CrCl = 20 \u2013 40 mL/min), recommended starting dose is 0.5 mg orally before each meal. ( 2.2 ) Dose modifications are required when used concominantly with some medications. ( 2.3 , 7 )",
    "warningsAndPrecautions_original": "Repaglinide Tablets, USP are available as follows:\n                  0.5 mg, white to off-white colored, round tablet debossed with\n \n  \u2018CE\u2019on one side and\n \n  \u2018251\u2019on the other side.\n\n \n                  NDC 62135-946-90, bottle of 90 tablets\n                  1 mg, yellow to pale yellow, slightly mottled, round tablet debossed with\n \n  \u2018CE\u2019on one side and\n \n  \u2018252\u2019on the other side.\n\n \n                  NDC 62135-947-90, bottle of 90 tablets\n                  2 mg, yellow to pale yellow, slightly mottled, capsule shaped tablet debossed with\n \n  \u2018CE\u2019on one side and\n \n  \u2018253\u2019on the other side.\n\n \n                  NDC 62135-948-90, bottle of 90 tablets\n                  Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [see USP Controlled Room Temperature].\n                  Protect from moisture. Keep bottles tightly closed.\n                  Dispense in tight containers with safety closures.",
    "adverseReactions_original": "Repaglinide tablets are contraindicated in patients with:\n                  \n                     Concomitant use of gemfibrozil\n  \n   [see\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     Known hypersensitivity to repaglinide or any inactive ingredients.",
    "drug": [
        {
            "name": "Repaglinide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8805"
        }
    ]
}